Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week.
COVID-19
SARS-CoV-2
cardiovascular medications
drug-drug interactions
nirmatrelvir-ritonavir
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
15 11 2022
15 11 2022
Historique:
received:
21
07
2022
revised:
29
08
2022
accepted:
29
08
2022
pubmed:
16
10
2022
medline:
15
11
2022
entrez:
15
10
2022
Statut:
ppublish
Résumé
Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe disease. Patients with cardiovascular risk factors and cardiovascular disease are at a high risk of developing adverse events from COVID-19 and as a result have a higher likelihood of receiving NMVr. Ritonavir, the pharmaceutical enhancer used in NMVr, is an inhibitor of the enzymes of CYP450 pathway, particularly CYP3A4 and to a lesser degree CYP2D6, and affects the P-glycoprotein pump. Co-administration of NMVr with medications commonly used to manage cardiovascular conditions can potentially cause significant drug-drug interactions and may lead to severe adverse effects. It is crucial to be aware of such interactions and take appropriate measures to avoid them. In this review, we discuss potential drug-drug interactions between NMVr and commonly used cardiovascular medications based on their pharmacokinetics and pharmacodynamic properties.
Identifiants
pubmed: 36243540
pii: S0735-1097(22)06825-5
doi: 10.1016/j.jacc.2022.08.800
pmc: PMC9580069
pii:
doi:
Substances chimiques
Ritonavir
O3J8G9O825
Cardiovascular Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1912-1924Informations de copyright
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
Xenobiotica. 2018 Mar;48(3):300-313
pubmed: 28281384
Ther Drug Monit. 2020 Aug;42(4):652-653
pubmed: 32433189
P T. 2013 Nov;38(11):656-66
pubmed: 24391386
Circulation. 1999 Aug 17;100(7):700-5
pubmed: 10449690
J Clin Pharmacol. 2000 Dec;40(12 Pt 1):1312-22
pubmed: 11185629
Clin Infect Dis. 2022 Jun 02;:
pubmed: 35653428
Am J Transplant. 2022 Jul;22(7):1925-1926
pubmed: 35015924
J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):390-6
pubmed: 25202920
Drug Metab Dispos. 2002 Dec;30(12):1344-51
pubmed: 12433801
Xenobiotica. 2010 Mar;40(3):163-76
pubmed: 20102298
FEBS Lett. 1999 Jun 11;452(3):165-9
pubmed: 10386583
J Clin Transl Endocrinol. 2017 Feb 22;8:6-14
pubmed: 29067253
Am J Cardiovasc Drugs. 2017 Oct;17(5):375-389
pubmed: 28364370
Clin Pharmacokinet. 2002;41(1):7-17
pubmed: 11825094
Pharmacotherapy. 2007 Jun;27(6):874-87
pubmed: 17542770
Pharmacol Ther. 1997;73(1):67-74
pubmed: 9014207
Clin Pharmacokinet. 2018 Oct;57(10):1347-1354
pubmed: 29453687
Arthritis Rheum. 2011 Aug;63(8):2226-37
pubmed: 21480191
Pharmacotherapy. 2016 Jan;36(1):49-56
pubmed: 26799348
J Pharmacol Exp Ther. 2014 Jul;350(1):130-43
pubmed: 24769543
P T. 2015 Dec;40(12):810-4
pubmed: 26681903
Br J Clin Pharmacol. 2019 Mar;85(3):508-515
pubmed: 30575989
Ann Pharmacother. 2014 Jun;48(6):734-40
pubmed: 24615627
J Pharm Technol. 2022 Dec;38(6):349-359
pubmed: 36311309
CMAJ. 2015 Jan 6;187(1):36-43
pubmed: 25225224
Drugs. 2013 Oct;73(15):1681-709
pubmed: 24114622
Clin Pharmacokinet. 2005;44(12):1329-42
pubmed: 16372830
Clin Pharmacokinet. 2006;45(5):469-91
pubmed: 16640453
J Acquir Immune Defic Syndr. 2006 May;42(1):52-60
pubmed: 16639344
Br J Clin Pharmacol. 2013 Sep;76(3):455-66
pubmed: 23305158
J Chemother. 2018 Sep;30(5):296-303
pubmed: 30843777
Clin Pharmacokinet. 2002;41(14):1195-211
pubmed: 12405866
Br J Clin Pharmacol. 2000 Aug;50(2):99-107
pubmed: 10930961
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054
Clin Infect Dis. 2022 Aug 20;:
pubmed: 35986628
Clin Pharmacokinet. 2010 Aug;49(8):493-507
pubmed: 20608753
Scand J Infect Dis. 2011 Mar;43(3):239-40
pubmed: 20942777
Clin Pharmacol Ther. 2004 Jul;76(1):73-84
pubmed: 15229466
Clin Pharmacol Ther. 2022 Oct;112(4):803-807
pubmed: 35712802
Antivir Ther. 2018;23(5):467-469
pubmed: 29300165
Cardiovasc Drugs Ther. 2021 Jun;35(3):427-440
pubmed: 32918656